Trial · NCT02432274
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
NCT02432274, Phase 1, Phase 2, Completed, Eisai Limited; results first posted 2020-09-17
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma. Trials, record NCT02432274. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02432274
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
- NCT number
- NCT02432274
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 117 participants, actual
- Lead sponsor
- Eisai Limited
- Conditions
- Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
- Interventions
- Lenvatinib, Lenvatinib, Lenvatinib, Lenvatinib, Lenvatinib, Ifosfamide, Etoposide, Ifosfamide, Etoposide
- First posted
- 2015-05-04
- Last updated
- 2023-07-11
- Other registries' IDs
- eudract:2013-005534-38
- Results first posted
- 2020-09-17
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cohort 1: Recommended Dose (RD) of Lenvatinib | Cycle 1 (28 days) | RD was defined as the dose that had a dose limiting toxicity (DLT) rate closest to the targeted 20% rate. DLT was an adverse drug reaction and was assessed according to common terminology criteria for adverse events (CTCAE) version (v) 4.03 defined as 1) Grade 4 neutropenia for greater than or equal to (\>=) 7 days, 2) Grade \>=3 thrombocytopenia with bleeding, or lasting greater than (\>) 7 days, 3) Grade \>=3 febrile neutropenia, 4) Next course of chemotherapy delayed for \>=7 days, 5) Grade \>=3 non-hematologic toxicity persisting \>7 days optimal supportive care, 6) Grade 4 hypertension, confirmed systolic or diastolic blood pressure \>25 millimeters of mercury (mmHg) above the 95th percentile for age, or an elevated diastolic blood pressure (that is, \>95th percentile for age) not controlled by a single antihypertensive medication within 14 days of use, 7) Grade 3 proteinuria, 8) Any recurrent Grade 2 non-hematological toxicity requiring \>=2 interruption and dose reductions. |
| Primary | Cohort 2A: Number of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR) | From date of first dose of study drug until first documentation of PD or death, whichever occurred first (until the data cut-off date, 31 May 2019) | OR was defined as participants with best overall response (BOR) of CR or PR as assessed by investigator based on response evaluation criteria in solid tumors (RECIST) version (v) 1.1. For OR, the BOR was defined as the best response (CR or PR for \>4 weeks) recorded from the start of the treatment until PD or death whichever occurred first. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameter (SOD) of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. |
| Primary | Cohort 2A: Number of Participants With Best Overall Response (BOR) | From first dose of study drug until PD or death, whichever occurred first (until the data cut-off date, 31 May 2019) | BOR was defined as the best response of CR or PR for \>4 weeks or SD for \>=7 weeks recorded from the start of the treatment until PD or death, whichever occurred first based on RECIST v1.1. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. |
| Primary | Cohorts 2B and 3B: Progression-free Survival (PFS) Rate at Month 4 | At Month 4 | Progression free survival at Month 4 (PFS-4) rate was defined as the percentage of participants who were alive and without PD at Month 4 after the first dose of study drug, based on RECIST v1.1, using a binomial proportion with corresponding 95% confidence interval (CI). PD: \>= 20% increase in sum of diameters of target lesions, reference-smallest sum recorded in study (sum at baseline if that was smallest). Sum of diameters must have absolute increase of \>=5 mm. Appearance of \>=1 new lesions also considered PD. |
| Primary | Cohort 3A: Recommended Dose (RD) of Lenvatinib When Given in Combination With Etoposide and Ifosfamide | Cycle 1 (21 days) | RD of lenvatinib when given in combination with ifosfamide and etoposide was defined as dose that resulted in no more than 1 DLT per 6 participants,or hematologic DLT in 1 participant and nonhematologic DLT in another participant per 6 participants,upon repeating same dose level.DLT was adverse drug reaction and assessed per CTCAE v4.03 defined as 1)Grade 4 neutropenia for \>=10 days,2)Grade \>=3 thrombocytopenia with bleeding,or lasting \>=10 days,3)Grade \>=3 febrile neutropenia lasting \>=7 days,4)Next course of chemotherapy delayed for \>=7 days,5)Grade \>=3 nonhematologic toxicity persisting \>7 days despite optimal supportive care,6)Grade 4 hypertension,confirmed systolic or diastolic blood pressure \>25 mmHg above 95th percentile for age,or elevated diastolic blood pressure(\>95th percentile for age)not controlled by single antihypertensive medication within 14 days use,7)Grade 3 proteinuria,8)Any recurrent Grade 2 nonhematological toxicity requiring \>=2 interruption and dose reductions. |
| Secondary | Cohorts 1, 2B, 3A, and 3B: Number of Participants With Best Overall Response (BOR) | From date of first dose of study drug until PD or death, whichever occurred first (Cohort 1, Cohort 2B: until the data cut-off date, 31 May 2019; Cohort 3A, Cohort 3B: until the data cut-off date, 18 July 2019) | BOR: best response of CR or PR for \>4 weeks or SD for \>=7 weeks from first dose, recorded from start of treatment until PD or death, whichever occurred first based on RECIST v1.1. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have reduction in their short axis \<10 mm. PR: at least 30% decrease in SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD was defined as: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Not evaluable (NE) means BOR of NE or SD of \<7 weeks duration. Unknown means no data were available on the case report form. |
| Secondary | Cohorts 1, 2B, 3A, and 3B: Objective Response Rate (ORR) | From date of first dose of study drug until PD or death, whichever occurred first (Cohort 1, Cohort 2B: until the data cut-off date, 31 May 2019; Cohort 3A, Cohort 3B: until the data cut-off date, 18 July 2019) | ORR was defined as the percentage of participants with a BOR of CR or PR for \>4 weeks or SD for \>=7 weeks as assessed by investigator based on RECIST v1.1, recorded from start of study treatment until PD or death whichever occurred first. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. 95% CI of the ORR were calculated according to Clopper and Pearson method. |
| Secondary | Cohorts 1, 2A, 2B, 3A and 3B: Duration of Response (DOR) | First documentation of CR/PR until first documentation of PD (Cohort 1, Cohort 2A, Cohort 2B: until the data cut-off date, 31 May 2019; Cohort 3A, Cohort 3B: until the data cut-off date, 18 July 2019) | DOR was defined as time in months from the first documentation confirmed CR or PR until the first documentation of confirmed PD as assessed by investigator based on RECIST v1.1. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. 95% CI for the median were calculated according to Brookmeyer and Crowley method. |
| Secondary | Cohorts 1, 2A, 2B, 3A and 3B: Number of Participants Who Experienced Disease Control | From first dose of study drug until PD or death, whichever occurred first (Cohort 1, Cohort 2A, Cohort 2B: until the data cut-off date, 31 May 2019; Cohort 3A, Cohort 3B: until the data cut-off date, 18 July 2019) | Participants were defined as having disease control if they had a BOR of CR or PR for \>4 weeks, or SD (minimum duration from first dose to SD \>=7 weeks) or if participants had a BOR of CR or Non-CR/Non-PD (minimum duration from first dose to Non-CR/Non-PD \>=7 weeks) per RECIST v1.1, recorded from first dose until PD or death whichever occurred first. CR: disappearance of all target/non-target lesions (non-lymph nodes). All pathological lymph nodes (target/non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest SOD. Non-CR/Non-PD: persistence of 1 or more non-target lesions, maintenance of tumor marker level above the normal limits. |
| Secondary | Cohorts 1, 2A, 2B, 3A and 3B: Number of Participants Experienced Clinical Benefit | From first dose of study drug until PD or death, whichever occurred first (Cohort 1, Cohort 2A, Cohort 2B: until the data cut-off date, 31 May 2019; Cohort 3A, Cohort 3B: until the data cut-off date, 18 July 2019) | Participants were defined as having clinical benefit if they had a BOR of CR or PR for \>4 weeks or durable SD (lasting \>=23 weeks) or if participants had a BOR of CR or durable Non-CR/Non-PD (lasting \>=23 weeks) as per RECIST v1.1, recorded from first dose until PD or death whichever occurred first. CR: disappearance of all target/non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target/non-target) must have a reduction in their short axis \<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. Non-CR/Non-PD:persistence of 1 or more non-target lesions and maintenance of tumor marker level above the normal limits. |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes21
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cohort 1: Recommended Dose (RD) of Lenvatinib | Cycle 1 (28 days) | Safety analysis set included all participants who received any study drug and had at least one post-baseline safety evaluation. | milligram per square meter (mg/m^2) | NUMBER |
| PRIMARY | Cohort 2A: Number of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR) | From date of first dose of study drug until first documentation of PD or death, whichever occurred first (until the data cut-off date, 31 May 2019) | Full analysis set included all enrolled participants who did not fail study screening. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Cohort 2A: Number of Participants With Best Overall Response (BOR) | From first dose of study drug until PD or death, whichever occurred first (until the data cut-off date, 31 May 2019) | Full analysis set included all enrolled participants who did not fail study screening. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Cohorts 2B and 3B: Progression-free Survival (PFS) Rate at Month 4 | At Month 4 | PFS-4 evaluable set included all participants treated with study drug for at least 4 months or those who died or radiologically progressed within 4 months after first dose, or received anticancer treatment within 4 months after first dose. | percentage of participants | NUMBER |
| PRIMARY | Cohort 3A: Recommended Dose (RD) of Lenvatinib When Given in Combination With Etoposide and Ifosfamide | Cycle 1 (21 days) | Safety analysis set included all participants who received any study drug and had at least one post-baseline safety evaluation. | milligram per square meter (mg/m^2) | NUMBER |
| SECONDARY | Cohorts 1, 2B, 3A, and 3B: Number of Participants With Best Overall Response (BOR) | From date of first dose of study drug until PD or death, whichever occurred first (Cohort 1, Cohort 2B: until the data cut-off date, 31 May 2019; Cohort 3A, Cohort 3B: until the data cut-off date, 18 July 2019) | Full analysis set included all enrolled participants who did not fail study screening. Here overall number of participants analyzed signifies participants who were evaluable for this outcome measure. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Cohorts 1, 2B, 3A, and 3B: Objective Response Rate (ORR) | From date of first dose of study drug until PD or death, whichever occurred first (Cohort 1, Cohort 2B: until the data cut-off date, 31 May 2019; Cohort 3A, Cohort 3B: until the data cut-off date, 18 July 2019) | Full analysis set included all enrolled participants who did not fail study screening. Here overall number of participants analyzed signifies participants who were evaluable for this outcome measure. | percentage of participants | NUMBER |
| SECONDARY | Cohorts 1, 2A, 2B, 3A and 3B: Duration of Response (DOR) | First documentation of CR/PR until first documentation of PD (Cohort 1, Cohort 2A, Cohort 2B: until the data cut-off date, 31 May 2019; Cohort 3A, Cohort 3B: until the data cut-off date, 18 July 2019) | Full analysis set included all enrolled participants who did not fail study screening. Here overall number of participants analyzed, N signifies participants who were evaluable for this measure. Here, N for Cohort 1 (Lenvatinib 11, 14, 17 mg/m\^2) and Cohort 3A (Lenvatinib 14 mg/m\^2) is zero as there were no events of CR or PR in these arms. | months | MEDIAN |
| SECONDARY | Cohorts 1, 2A, 2B, 3A and 3B: Number of Participants Who Experienced Disease Control | From first dose of study drug until PD or death, whichever occurred first (Cohort 1, Cohort 2A, Cohort 2B: until the data cut-off date, 31 May 2019; Cohort 3A, Cohort 3B: until the data cut-off date, 18 July 2019) | Full analysis set included all enrolled participants who did not fail study screening. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Cohorts 1, 2A, 2B, 3A and 3B: Number of Participants Experienced Clinical Benefit | From first dose of study drug until PD or death, whichever occurred first (Cohort 1, Cohort 2A, Cohort 2B: until the data cut-off date, 31 May 2019; Cohort 3A, Cohort 3B: until the data cut-off date, 18 July 2019) | Full analysis set included all enrolled participants who did not fail study screening. | Participants | COUNT_OF_PARTICIPANTS |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 outcomesResults by group1,124
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cohort 1: Recommended Dose (RD) of Lenvatinib | Cohort 1: All Participants | 14 | milligram per square meter (mg/m^2) | ||
| Cohort 2A: Number of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR) | Cohort 2A, Single-agent Expansion, DTC: Lenvatinib 14 mg/m^2 | 1 | Participants | ||
| Cohort 2A: Number of Participants With Best Overall Response (BOR) | Cohort 2A, Single-agent Expansion, DTC: Lenvatinib 14 mg/m^2 | Complete Response | 0 | Participants | |
| Cohort 2A: Number of Participants With Best Overall Response (BOR) | Cohort 2A, Single-agent Expansion, DTC: Lenvatinib 14 mg/m^2 | Partial Response | 1 | Participants | |
| Cohort 2A: Number of Participants With Best Overall Response (BOR) | Cohort 2A, Single-agent Expansion, DTC: Lenvatinib 14 mg/m^2 | Stable Disease | 0 | Participants | |
| Cohorts 2B and 3B: Progression-free Survival (PFS) Rate at Month 4 | Cohort2B,Single-agentExpansion,Osteosarcoma:Lenvatinib14mg/m^2 | 32.1 | 95% Confidence Interval 15.9 to 52.4 | percentage of participants | |
| Cohorts 2B and 3B: Progression-free Survival (PFS) Rate at Month 4 | Cohort 3B, Combination Expansion: Lenvatinib 14 mg/m^2 | 66.7 | 95% Confidence Interval 38.4 to 88.2 | percentage of participants | |
| Cohort 3A: Recommended Dose (RD) of Lenvatinib When Given in Combination With Etoposide and Ifosfamide | Cohort 3A: All Participants | 14 | milligram per square meter (mg/m^2) | ||
| Cohorts 1, 2B, 3A, and 3B: Number of Participants With Best Overall Response (BOR) | Cohort 1, Single-agent Dose-finding: Lenvatinib 11 mg/m^2 | Complete Response | 0 | Participants | |
| Cohorts 1, 2B, 3A, and 3B: Number of Participants With Best Overall Response (BOR) | Cohort 1, Single-agent Dose-finding: Lenvatinib 14 mg/m^2 | Complete Response | 0 | Participants |
1 to 10 of 1,124Source ClinicalTrials.gov
See all 1,124 results by groupParticipant flow40
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cohort 1, Single-agent Dose-finding: Lenvatinib 11 mg/m^2 | 3 | |
| Overall Study | STARTED | Cohort 1, Single-agent Dose-finding: Lenvatinib 14 mg/m^2 | 9 | |
| Overall Study | STARTED | Cohort 1, Single-agent Dose-finding: Lenvatinib 17 mg/m^2 | 11 | |
| Overall Study | STARTED | Cohort 2A, Single-agent Expansion, DTC: Lenvatinib 14 mg/m^2 | 1 | |
| Overall Study | STARTED | Cohort2B,Single-agentExpansion,Osteosarcoma:Lenvatinib14mg/m^2 | 31 | |
| Overall Study | STARTED | Cohort 3A, Combination Dose-finding: Lenvatinib 11 mg/m^2 | 7 | |
| Overall Study | STARTED | Cohort 3A, Combination Dose-finding: Lenvatinib 14 mg/m^2 | 15 | |
| Overall Study | STARTED | Cohort 3B, Combination Expansion: Lenvatinib 14 mg/m^2 | 20 | |
| Overall Study | Underwent Run-in Period | Cohort 1, Single-agent Dose-finding: Lenvatinib 11 mg/m^2 | 1 | |
| Overall Study | Underwent Run-in Period | Cohort 1, Single-agent Dose-finding: Lenvatinib 14 mg/m^2 | 1 |
1 to 10 of 40Source ClinicalTrials.gov
See all 40 participant flowAdverse events4,158
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Lenvatinib 5 mg/m^2 | 0 | 2 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 1, Single-agent Dose-finding: Lenvatinib 11 mg/m^2 | 1 | 5 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 1, Single-agent Dose-finding: Lenvatinib 14 mg/m^2 | 2 | 11 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 1, Single-agent Dose-finding: Lenvatinib 17 mg/m^2 | 1 | 7 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 2A, Single-agent Expansion, DTC: Lenvatinib 14 mg/m^2 | 0 | 1 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort2B,Single-agentExpansion,Osteosarcoma:Lenvatinib14mg/m^2 | 5 | 31 | 7 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 3A, Combination Dose-finding: Lenvatinib 11 mg/m^2 | 9 | 11 | 43 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 3A, Combination Dose-finding: Lenvatinib 14 mg/m^2 | 7 | 11 | 29 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 3B, Combination Expansion: Lenvatinib 14 mg/m^2 | 15 | 20 | 77 |
| other | Lymphopenia | Blood and lymphatic system disorders | Lenvatinib 5 mg/m^2 | 0 | 2 | 0 |
1 to 10 of 4,158Source ClinicalTrials.gov
See all 4,158 adverse eventsAdverse event totals27
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Lenvatinib 5 mg/m^2 | 0 | 2 |
| Total, all-cause mortality | Cohort 1, Single-agent Dose-finding: Lenvatinib 11 mg/m^2 | 2 | 5 |
| Total, all-cause mortality | Cohort 1, Single-agent Dose-finding: Lenvatinib 14 mg/m^2 | 7 | 11 |
| Total, all-cause mortality | Cohort 1, Single-agent Dose-finding: Lenvatinib 17 mg/m^2 | 6 | 7 |
| Total, all-cause mortality | Cohort 2A, Single-agent Expansion, DTC: Lenvatinib 14 mg/m^2 | 0 | 1 |
| Total, all-cause mortality | Cohort2B,Single-agentExpansion,Osteosarcoma:Lenvatinib14mg/m^2 | 27 | 31 |
| Total, all-cause mortality | Cohort 3A, Combination Dose-finding: Lenvatinib 11 mg/m^2 | 10 | 11 |
| Total, all-cause mortality | Cohort 3A, Combination Dose-finding: Lenvatinib 14 mg/m^2 | 6 | 11 |
| Total, all-cause mortality | Cohort 3B, Combination Expansion: Lenvatinib 14 mg/m^2 | 14 | 20 |
| Total, other adverse events | Lenvatinib 5 mg/m^2 | 2 | 2 |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 adverse event totalsPapers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02432274
GET https://conductscience.org/api/trials/v1/NCT02432274/registered?page=2